Introduction
============

Determining the safe starting dose for humans is one of the most important steps before any new biopharmaceutical product under development can enter clinical testing for the first time. Ideally, the starting dose should be low not to cause any harm in humans, while it is expected to be not too low for efficacy, thereby reducing the number of patients exposed to ineffective doses in the first-in-human (FIH) clinical trials.[@b1-dddt-10-4005] The regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have published guidance documents to select the maximum recommended starting dose (MRSD) in the FIH study.[@b2-dddt-10-4005],[@b3-dddt-10-4005] The FDA guidance has been used in many FIH studies with new chemical entities of low-molecular weight, although it is also applicable to the FIH studies with biological agents. The emphasis in the FDA guidance is placed on the no observed adverse effects level (NOAEL) assessed in preclinical toxicology studies.[@b2-dddt-10-4005] The NOAEL is then converted into the human equivalence dose by applying an appropriate scaling factors to adjust for body surface area among different species.[@b2-dddt-10-4005] In contrast, the EMA guidance stresses the minimal anticipated biological effect level (MABEL) approach, in which all in vitro and in vivo information will be taken into consideration.[@b3-dddt-10-4005] The NOAEL- or the MABEL-derived human equivalence dose can be reduced further by applying the safety factor, a number by which the calculated human equivalence dose is divided to increase the assurance that the first dose will not cause toxicity in humans.

Since the 1980s, monoclonal antibodies (mAbs) have been actively incorporated into clinical medicine as a beneficial therapeutic option, particularly in oncology and immunology.[@b4-dddt-10-4005] However, protein-based drugs such as mAbs can have more uncertain safety profiles than those of chemistry-based drugs before an FIH study is conducted. For example, a severe life-threatening cytokine storm was developed in all the subjects who received the active drug in FIH study with TGN1412, a superagonist mAb against CD28, although a conservatively low starting dose was administered derived from the NOAEL (ie, a large safety factor of 160).[@b5-dddt-10-4005] This tragic incident highlighted the importance of and difficulties in selecting the safest maximum starting dose in FIH studies with mAbs.[@b6-dddt-10-4005] After the incident in the FIH study of TGN1412, several publications have proposed various ways to determine MRSD for FIH studies with biological agents. Many of these follow-up publications emphasized that MRSD for the FIH study with novel biological agents should be chosen after taking into account multiple points, for example, different endpoints, interspecies scaling, and safety factors.[@b7-dddt-10-4005],[@b8-dddt-10-4005] In support of this notion, a recent review found that the preclinical animal models and key toxicity parameters used to determine the starting dose for FIH studies with molecularly targeted agents in cancer patients were variable and heterogeneous.[@b9-dddt-10-4005] To the best of our knowledge, however, no investigation has reported how MRSD was determined in FIH studies with mAbs and which factors were associated with the choice of MRSD determination methods. Furthermore, the consequences of various MRSD determination methods have not been assessed, particularly in terms of safety and efficiency in achieving the objectives of FIH clinical trials. On the basis of this understanding, the objectives of the present study were 1) to evaluate MRSD determination methods employed in FIH studies with mAbs, 2) to identify factors associated with choosing one method over the others, and 3) to compare the safety and efficiency of each MRSD determination method. To achieve these objectives, we performed a systematic review of the papers that reported the results of FIH studies with mAbs from 1990 to 2013.

Materials and methods
=====================

Literature search and selection of the FIH studies
--------------------------------------------------

To construct a database for the FIH studies with mAbs, we searched PubMed using the combination of the following terms: clinical trial, phase I or phase 1, first-in-human or first-in-man, first-time-in-human or first-time-in-man, starting dose or initial dose, and mAb. The literature search was complemented by an additional manual search of the references from the published papers and reviews focusing on mAbs. Eligible studies had to meet all of the following inclusion criteria: 1) the full text was available or there was at least a clear indication of how the MRSD was determined in the abstract or proceedings, 2) the text was written in English, and 3) the studies were published between January 1, 1990 and December 31, 2013.

Classification of MRSD determination methods and data extraction
----------------------------------------------------------------

If papers explicitly stated that the MRSD was determined based on a NOAEL, MABEL, minimum effective dose (MED), or pharmacologically active dose (PAD), they were classified as the respective dose- or level-based. Although a paper did not clearly indicate the MRSD determination method, it was also classified as NOAEL-, MABEL-, MED-, or PAD-based if the paper presented other information or supplemental data that enabled us to identify which method was used. For example, if a paper emphasized that no toxicity was found in the preclinical animal model up to a certain dose, which was used as the basis for determining the MRSD in humans, the method was NOAEL-based. Similarly, if the MRSD was determined from a dose identified in preclinical models that produced any or minimal pharmacological effect, the paper was classified as PAD- or MED-based, respectively. However, if animal pharmacokinetic (PK) data were the basis of MRSD determination or if a PK model was used to estimate the human PK parameters, which eventually resulted in the MRSD, the method was PK model-based. If the information about the receptor occupancy or other biomarkers was used to determine the MRSD, the method was pharmacodynamic (PD) model-based. If a PK--PD modeling approach was used to determine the MABEL, however, the paper was classified as MABEL-based. Because there were some similarities among MRSD determination methods, they were further grouped as follows: 1) MABEL- or MED-based (ie, MRSD was selected based on a dose associated with the minimal pharmacological effect) or 2) model-based (ie, PK, PD, or PK--PD, in which MRSD was determined using a model-based approach).

We also collected the information about the factors that could have been associated with the choice of MRSD determination method: publication year, therapeutic area (ie, oncology, immunology, infection, and others), and antibody type (ie, murine, chimeric, humanized, fully human, and others). Because the MABEL-based approach was officially first introduced in the EMA guidance in 2007, partly prompted by the TGN1412 incident,[@b3-dddt-10-4005] we categorized the publication year into three periods: before 2007 (ie, 1990--2007) and two 3-year periods after 2007 (ie, 2008--2010 and 2011--2013) to investigate the impact of the EMA guidance.

Furthermore, we extracted or derived the safety factor using the information available in the paper. In addition, we collected the safety result after the first dose and the number of dose escalation steps to evaluate the consequence of each MRSD determination method.

Two authors (HYS and HL) independently reviewed the papers and performed data extraction. The extracted data were then cross-checked for concurrence, and any differences were discussed until an agreement was reached.

Statistical analysis
--------------------

Safety factor and MRSD determination method were summarized using descriptive statistics. The Fisher's exact test was performed to analyze whether MRSD determination method was significantly affected by the publication year, therapeutic area, and the type of mAbs. To test whether the median safety factor and the mean number of dose escalation steps were significantly different by MRSD determination method, the Kruskal--Wallis and the analysis of variance tests were performed, respectively. The SAS statistical software (version 9.4; SAS Institute, Inc., Cary, NC, USA) was used for the statistical analysis, and a two-tailed *P*-value ≤0.05 was considered statistically significant.

Results
=======

Study identification
--------------------

The literature search identified 140 candidate FIH studies with mAbs, 61 of which were excluded because they did not meet the selection criteria: full text unavailable (n=58) or not in English (n=1); published before January 1, 1990 or after December 31, 2013 (n=2). Hence, a total of 79 FIH studies were included in the final study database ([Table S1](#SD1-dddt-10-4005){ref-type="supplementary-material"}). Overall, the majority of FIH studies with mAbs were performed in oncology (n=41, 51.9%), followed by immunology (n=14, 17.7%) and infection (n=10, 12.7%). The number of FIH studies with fully human antibodies and humanized antibodies has drastically increased since the early 2000s, whereas the number of FIH studies with murine or chimeric antibodies remained steadily low during the entire period ([Figure 1](#f1-dddt-10-4005){ref-type="fig"}).

MRSD determination method
-------------------------

Of 79 FIH studies with mAbs included in the study database, 49 studies (62.0%) clearly indicated how the MRSD was determined, whereas the remaining 30 studies (38.0%) did not report the MRSD determination method ([Figure 2](#f2-dddt-10-4005){ref-type="fig"}). Of the 49 studies that reported the MRSD determination method, more than one-third used the NOAEL-based approach (n=17, 34.7%), followed by the PAD-based approach (n=13, 26.5%) and the MABEL- or MED-based approach (n=11, 22.4%). The model-based approach was the least common method (n=8, 16.3%).

Factors associated with the choice of MRSD determination method
---------------------------------------------------------------

The more recent the publications were the more frequently they reported which method was used to determine the MRSD. Almost 90% of the studies published from 2011 to 2013 clearly indicated which method was used to determine the MRSD, whereas only half of the studies published before 2007 did ([Table 1](#t1-dddt-10-4005){ref-type="table"}). The MABEL- or MED-based approach was used more frequently in 2011--2013 than in 1990--2007 (31.6% vs 6.3%, [Table 1](#t1-dddt-10-4005){ref-type="table"}). Notably, the MABEL-based approach was not used until 2005 ([Table S1](#SD1-dddt-10-4005){ref-type="supplementary-material"}; [Figure 3](#f3-dddt-10-4005){ref-type="fig"}). In contrast, the proportions of the other MRSD determination methods, particularly the model-based approach, did not appear to change much over the entire period of 1990--2013. Collectively, MRSD determination method varied significantly by publication year (*P*=0.036, [Table 1](#t1-dddt-10-4005){ref-type="table"}), whereas therapeutic area or antibody type was not significantly associated with the choice of MRSD determination method (*P*=0.995 and 0.982, respectively, [Table 1](#t1-dddt-10-4005){ref-type="table"}).

Safety factor and consequence of MRSD determination method
----------------------------------------------------------

The median safety factor was numerically much lower for the MABEL- or MED-based approach than for the other approaches, although this difference failed to reach statistical significance (10 vs 32.2--53, *P*=0.416, [Table 2](#t2-dddt-10-4005){ref-type="table"}). Fourteen studies (17.7%) indicated that the first dose was safe, in which the MRSD was determined by the NOAEL-based (n=6) and the MABEL- or MED-based approaches (n=6). Only one study reported the first dose was not safe, in which the NOAEL was the basis for MRSD determination. The mean number of dose escalation steps was comparable among the different MRSD determination methods (*P*=0.177, [Figure 4](#f4-dddt-10-4005){ref-type="fig"}).

Discussion
==========

We have found that the NOAEL-based approach was still the most commonly used MRSD determination method for FIH studies with mAbs, while the model-based approach was used far less frequently. Our results showed that more than one-third of the FIH studies employed the NOAEL-based approach, which was double the number of studies using the model-based approach (34.7% vs 16.3%, [Figure 2](#f2-dddt-10-4005){ref-type="fig"}). This trend was rather disappointing, given that the usefulness of the model-based approach has been repeatedly emphasized in determining the MRSD.[@b10-dddt-10-4005]--[@b13-dddt-10-4005] For example, a PK--PD model derived from cynomolgus monkeys enabled choosing 0.01 mg/kg as the MRSD for the FIH study with TRC105, an antibody with antiangiogenic effect to solid tumors. On the basis of the PK--PD model, the MRSD would successfully result in concentrations above the dissociation constant for the antibody, leading to a pharmacologic effect in humans.[@b14-dddt-10-4005] However, the infrequent use of the model-based approach to determine the MRSD can be attributed to the fact that animal data may not be available in sufficient detail to construct a model at the time of the FIH studies with mAbs.[@b2-dddt-10-4005],[@b11-dddt-10-4005],[@b15-dddt-10-4005] Furthermore, concerns about interspecies differences in bioavailability and metabolism could be another factor that has prevented the model-based approach from being applied more frequently in FIH studies with mAbs.[@b16-dddt-10-4005]

Our results also showed that publication year was significantly associated with the choice of MRSD determination method, which was demonstrated in two ways. First, the proportion of FIH studies not reporting the MRSD determination method fell sharply to 10.5% in 2011--2013 from 42.9% in 2008--2010 and 50.0% in 1990--2007 ([Table 1](#t1-dddt-10-4005){ref-type="table"}; [Figure 3](#f3-dddt-10-4005){ref-type="fig"}). It is encouraging that more FIH studies started reporting the MRSD determination method because this not only indicates increased transparency, but also it may allow for evaluating whether a certain type of MRSD determination method was useful or not in a particular study setting. Second, the MABEL- or MED-based approaches were more frequently used in 2011--2013 (31.6%) than in 1990--2007 (6.2%) and 2008--2010 (10.7%, [Table 1](#t1-dddt-10-4005){ref-type="table"}). In particular, the first MABEL-based FIH study with mAbs was published in 2005, followed by another in 2007 and six during 2010--2013 ([Table S1](#SD1-dddt-10-4005){ref-type="supplementary-material"}). This sharp increase during the latest period certainly reflects the impact of the tragic TGN1412 incident and the EMA guidance that followed the incident, which strongly recommended the use of the MABEL-based approach to determine MRSD.[@b8-dddt-10-4005],[@b17-dddt-10-4005] This trend is expected to continue in the future given the heightened concern about the potential safety issues of biological agents including mAbs. However, the MABEL-based approach requires extensive knowledge regarding the pharmacological mechanisms and their integration, preferably via PK--PD modeling.[@b10-dddt-10-4005],[@b18-dddt-10-4005]

The present study indicates that the safety factor varied widely by MRSD determination method. Namely, the MABEL- or MED-based approaches had much smaller median values of safety factor than the other MRSD determination methods ([Table 2](#t2-dddt-10-4005){ref-type="table"}). The safety factor accounts for uncertainties such as potential interspecies differences and thereby serves as an additional means of assuring that toxicity dose not develop in humans at the first dose in FIH studies.[@b19-dddt-10-4005] Therefore, smaller safety factors indicated greater confidence for human safety at the time of FIH studies.[@b2-dddt-10-4005] The MABEL-based approach always results in a smaller human equivalence dose than the other MRSD determination methods, particularly the NOAEL-based approach.[@b20-dddt-10-4005],[@b21-dddt-10-4005] Therefore, the safety factor tends to be smaller with the MABEL-based approach than with the other methods, as shown in our results.

Although the MABEL-based approach came up with an MRSD lower than those derived by the other approaches, the average number of dose escalation steps was similar ([Figure 4](#f4-dddt-10-4005){ref-type="fig"}). Fewer dose escalation steps indicated more efficient FIH studies. Therefore, the MABEL-based approach did not appear to be inferior to the other MRSD determination methods. Furthermore, more than half (6/11=54.5%) of the papers that employed the MABEL-based approach explicitly indicated that the first dose was safe, which was almost 20% points higher than that with the NOAEL-based approach (6/17=35.3%). Of course, this interpretation needs caution because \>80% of the papers did not explicitly mention about the safety results after the first dose.

The major limitation of the present study was the possibility of misclassifying MRSD determination method, particularly between the model- and MABEL-based approaches. Because the EMA guidance suggests that "all information available from PK/PD data ... wherever possible ... should be *integrated in a PK/PD modeling approach* for the determination of the MABEL (emphasis added)"

some FIH studies classified as using the model-based approach had, in fact, used the MABEL-based approach. However, this possible misclassification was very unlikely to influence our final conclusion because only a small number of FIH studies (n=8, 10.1%, [Table 2](#t2-dddt-10-4005){ref-type="table"}) were classified as model-based. Another limitation was that the MRSD determination method was not identifiable in 30 (=38%) FIH studies with mAbs because the authors did not report which method was used. Although our study database was constructed by a thorough literature search, further studies are warranted to circumvent this type of publication bias.[@b22-dddt-10-4005]

Conclusion
==========

We anticipate that the MABEL-based approach will be more frequently used in FIH studies with mAbs in the future, while the NOAEL-based approach is still likely to be the most commonly used method. The MABEL-based approach appears to be safer and as efficient as the other MRSD determination methods for achieving the objectives of FIH clinical trials faster. To the best of our knowledge, this is the first report showing the rapid acceptance of the MABEL-based approach in FIH studies with mAbs, reinforcing the impact of the EMA guidance. Our study can also illuminate the trends of the choice of MRSD determination methods, which may contribute to a safer design and conduct of FIH studies with mAbs in humans.

Supplementary material
======================

###### 

Study characteristics

  Reference                                      Year   Biologicals                 Therapeutic area                                       Target of action                    Type of action    Antibody type   MRSD determination method   Preclinical model       Safety factor[\*](#tfn8-dddt-10-4005){ref-type="table-fn"}
  ---------------------------------------------- ------ --------------------------- ------------------------------------------------------ ----------------------------------- ----------------- --------------- --------------------------- ----------------------- ------------------------------------------------------------
  Drobyski et al[@b23-dddt-10-4005]              1991   MSL-109 (sevirumab)         Transplantation (related infection)                    CMV                                 Antagonist        Fully human     NOAEL-based                 Non-human primate       3.2
  Klein et al[@b24-dddt-10-4005]                 1991   B-E8                        Oncology (multiple myeloma)                            IL6                                 Antagonist        Murine          PAD-based                   In vitro                NR
  Maloney et al[@b25-dddt-10-4005]               1994   IDEC-C2B8 (rituximab)       Oncology (non-Hodgkin lymphoma)                        CD20                                Antagonist        Chimeric        NR                          Non-rodent              NR
  Handgretinger et al[@b26-dddt-10-4005]         1995   ch14.18                     Oncology (metastatic melanoma)                         GD2                                 Agonist           Chimeric        NR                          NR                      NR
  Brooks et al[@b27-dddt-10-4005]                1995   42/6 Antibody               Oncology (advanced cancer)                             Transferrin receptor                Antagonist        Murine          NR                          Rodent                  NR
  Everitt et al[@b28-dddt-10-4005]               1996   RSHZ19                      Infection (respiratory syncytial virus)                F protein                           Antagonist        Humanized       NR                          NR                      NR
  Vincenti et al[@b29-dddt-10-4005]              1997   Anti-tac (daclizumab)       Transplantation (graft vs host disease)                IL2R-alpha                          Antagonist        Humanized       NR                          NR                      NR
  Zaanen et al[@b30-dddt-10-4005]                1998   CNTO-328 (siltuximab)       Oncology (multiple myeloma)                            IL6                                 Antagonist        Chimeric        NR                          NR                      NR
  Bowen et al[@b31-dddt-10-4005]                 1998   Hu23F2G (rovelizumab)       Immunology (multiple sclerosis)                        CD11/CD18                           Antagonist        Humanized       NR                          NR                      NR
  Harder et al[@b32-dddt-10-4005]                1999   YM337                       Coagulative vascular disorder                          Glycoprotein IIb/IIIa               Antagonist        Humanized       Model-based                 Non-human primate       6.5
  Gottlieb et al[@b33-dddt-10-4005]              2000   hu1124 (efalizumab)         Immunology (psoriasis)                                 CD11a                               Antagonist        Humanized       NR                          NR                      NR
  Crombet et al[@b34-dddt-10-4005]               2001   ior egf/r3                  Oncology (brain tumor)                                 EGFR                                Antagonist        Murine          Model-based                 NR                      NR
  Gordon et al[@b35-dddt-10-4005]                2001   rhuMAb (bevacizumab)        Oncology (advanced cancer)                             VEGF                                Antagonist        Humanized       NR                          NR                      NR
  Verbon et al[@b36-dddt-10-4005]                2001   IC14                        Infection (sepsis)                                     CD14                                Antagonist        Chimeric        NR                          Non-rodent              NR
  Chow et al[@b37-dddt-10-4005]                  2002   SB 249417                   Coagulative vascular disorder                          Factor IX                           Antagonist        Humanized       PAD-based                   Non-rodent              32.2
  Posey et al[@b38-dddt-10-4005]                 2003   IMC-1C11                    Oncology (colorectal cancer)                           VEGFR2                              Antagonist        Chimeric        PAD-based                   Rodent                  NR
  Kauffman et al[@b39-dddt-10-4005]              2004   Anti-IL-12p40               Immunology (psoriasis)                                 p40 of IL12, IL23                   Antagonist        Fully human     NOAEL-based                 Non-rodent              161
  Bekker et al[@b40-dddt-10-4005]                2004   AMG 162 (denosumab)         Osteoporosis                                           RANKL                               Antagonist        Fully human     NR                          NR                      NR
  Agus et al[@b41-dddt-10-4005]                  2005   2C4 (pertuzumab)            Oncology (advanced solid tumor)                        HER2                                Antagonist        Humanized       Model-based                 Non-human primate       300
  Dowling et al[@b42-dddt-10-4005]               2005   cαStx2                      Infection (Shiga toxin-producing *Escherichia coli*)   Stx2                                Antagonist        Chimeric        PAD-based                   Rodent                  NR
  Pacey et al[@b43-dddt-10-4005]                 2005   HGS-ETR2 (lexatumumab)      Oncology (advanced solid tumor)                        TRAIL-R2                            Agonist           Fully human     PAD-based                   Rodent                  2
  Subramanian et al[@b44-dddt-10-4005]           2005   Pam                         Infection (anthrax)                                    Protective antigen                  Antagonist        Fully human     PAD-based                   Non-rodent              NR
  Ribas et al[@b45-dddt-10-4005]                 2005   CP-675,206 (tremelimumab)   Oncology (solid tumor)                                 CTLA4                               Antagonist        Fully human     MABEL-based                 Rodent and non-rodent   NR
  Reilley et al[@b46-dddt-10-4005]               2005   T1-2 (tefibazumab)          Infection (*Staphylococcus aureus*)                    Clumping factor A                   Antagonist        Humanized       NR                          NR                      NR
  Suntharalingam et al[@b47-dddt-10-4005]        2006   TGN1412                     Immunology                                             CD28                                Agonist           Humanized       NOAEL-based                 Non-human primate       160
  Ng et al[@b48-dddt-10-4005]                    2006   TRX1                        Immunology (autoimmune disease)                        CD4                                 Antagonist        Humanized       PAD-based                   Non-rodent              NR
  Lacy et al[@b49-dddt-10-4005]                  2006   CP-751,871 (figitumumab)    Oncology (multiple myeloma)                            IGF1R                               Antagonist        Fully human     NR                          NR                      NR
  Tabrizi and Roskos[@b50-dddt-10-4005]          2007   Anti-Muc18 antibody         Oncology (malignant melanoma)                          Muc18                               Antagonist        Murine          MABEL-based                 Non-human primate       1
  Tolcher et al[@b51-dddt-10-4005]               2007   HGS-ETR1 (mapatumumab)      Oncology (advanced solid tumor)                        TRAIL-R1, DR4                       Agonist           Fully human     NOAEL-based                 Non-rodent              1,290
  Vonderheide et al[@b52-dddt-10-4005]           2007   CP-870,893                  Oncology (advanced solid tumor)                        CD40                                Agonist           Fully human     NR                          NR                      NR
  Scott et al[@b53-dddt-10-4005]                 2007   ch806, 111 In-ch806         Oncology                                               EGFR                                Antagonist        Chimeric        NR                          NR                      NR
  Mullamitha et al[@b54-dddt-10-4005]            2007   CNTO 95                     Oncology (solid tumor)                                 α~v~ integrins                      Antagonist        Fully human     NR                          Rodent                  NR
  Furie et al[@b55-dddt-10-4005]                 2008   Belimumab                   Immunology (systemic lupus erythematosus)              B lymphocyte stimulator             Antagonist        Fully human     NOAEL-based                 Non-human primate       16
  Hagenbeek et al[@b56-dddt-10-4005]             2008   Ofatumumab                  Oncology (follicular lymphoma)                         CD20                                Antagonist        Fully human     PAD-based                   Rodent                  NR
  Bouman-Thio et al[@b57-dddt-10-4005]           2008   CNTO 528                    Erythropoiesis                                         Erythropoietin receptor             Agonist           Fully human     NR                          Rodent and non-Rodent   NR
  Bargou et al[@b58-dddt-10-4005]                2008   AMG 103 (blinatumomab)      Oncology (non-Hodgkin lymphoma)                        CD19, CD3ε                          Agonist           Bi-specific     NR                          NR                      NR
  Sznol et al[@b59-dddt-10-4005]                 2008   BMS-663513                  Oncology (advanced melanoma)                           CD137                               Agonist           Fully human     NR                          NR                      NR
  Mendelson et al[@b60-dddt-10-4005]             2008   CVX-045                     Oncology (advanced solid tumor)                        Thrombospondin                      Antagonist        Fully human     NR                          NR                      NR
  Taylor et al[@b61-dddt-10-4005]                2008   CDA-1                       Infection (*Clostridium difficile*)                    *C. difficile toxin A*              Antagonist        Humanized       NR                          Rodent                  NR
  Weisman et al[@b62-dddt-10-4005]               2009   BSYX-AMD (pagibaximab)      Infection (Staphylococcus)                             Lipoteichoic acid                   Antagonist        Chimeric        MED-based                   Rodent (rat)            NR
  Lazar et al[@b63-dddt-10-4005]                 2009   KBPA 101                    Infection (*Pseudomonas aeruginosa*)                   LPS *O*-polysaccharide              Antagonist        Fully human     NOAEL-based                 Rodent (mouse)          10
  Lachmann et al[@b64-dddt-10-4005]              2009   ACZ885 (canakinumab)        Immunology (cryopyrin-associated periodic syndrome)    IL1-beta                            Antagonist        Fully human     Model-based                 NR                      NR
  Herbst et al[@b65-dddt-10-4005]                2009   AMG 386                     Oncology (advanced solid tumor)                        Antiopoietin                        Antagonist        NR              NOAEL-based                 Rodent                  NR
  Tolcher et al[@b66-dddt-10-4005]               2009   AMG 479 (ganitumab)         Oncology                                               IGF1R                               Antagonist        Fully human     NOAEL-based                 Rodent and non-rodent   10
  Lum et al[@b67-dddt-10-4005]                   2009   U3-1287                     Oncology (advanced solid tumor)                        HER3                                Antagonist        Fully human     Model-based                 Rodent and non-rodent   NR
  White et al[@b68-dddt-10-4005]                 2009   MEDI-528                    Immunology (asthma)                                    IL9                                 Antagonist        Humanized       NR                          NR                      NR
  Gordon et al[@b69-dddt-10-4005]                2010   AMG 102                     Oncology (advanced solid tumor)                        HGF/SF                              Antagonist        Fully human     NOAEL-based                 Non-human primate       100
  Herbst et al[@b70-dddt-10-4005]                2010   AMG 655 (conatumumab)       Oncology (advanced solid tumor)                        DR5                                 Agonist           Fully human     PAD-based                   Non-human primate       322
  Camidge et al[@b71-dddt-10-4005]               2010   PRO95780                    Oncology (advanced tumor)                              DR5                                 Agonist           Fully human     MED-based                   NR                      10
  Spratlin et al[@b72-dddt-10-4005]              2010   IMC-1121B (ramucirumab)     Oncology (advanced solid tumor)                        VEGFR2                              Antagonist        Fully human     Model-based                 Non-human primate       NR
  Beigel et al[@b73-dddt-10-4005]                2010   MGAWN1                      Infection (West Nile Virus)                            Envelope glycoprotein               Antagonist        Humanized       NOAEL-based                 Rodent (rat)            53
  Burris et al[@b74-dddt-10-4005]                2010   RAV12                       Oncology (gastrointestinal cancer)                     RAAG12                              Agonist           Chimeric        NOAEL-based                 Non-rodent              33
  Verhamme et al[@b75-dddt-10-4005]              2010   TB-402                      Coagulative vascular disorder                          Factor VII                          Antagonist        Fully human     MABEL-based                 Rodent and non-rodent   10
  Krop et al[@b76-dddt-10-4005]                  2010   T-DM1                       Oncology (metastatic breast cancer)                    HER2                                Antagonist        Humanized       NOAEL-based                 Non-rodent              12
  Hussein et al[@b77-dddt-10-4005]               2010   Dacetuzumab                 Oncology (multiple myeloma)                            CD40                                Partial agonist   Humanized       NR                          NR                      NR
  Kuenen et al[@b78-dddt-10-4005]                2010   IMC-11F8 (necitumumab)      Oncology (advanced solid tumor)                        EGFR                                Antagonist        Fully human     NR                          NR                      NR
  Brahmer et al[@b79-dddt-10-4005]               2010   MDX-1106                    Oncology (solid tumor)                                 PD-1                                Antagonist        Fully human     NR                          NR                      NR
  Genovese et al[@b80-dddt-10-4005]              2010   LY2439821                   Immunology (rheumatoid arthritis)                      IL17                                Antagonist        Humanized       NR                          NR                      NR
  Adler et al[@b81-dddt-10-4005]                 2010   FG-3019                     Diabetic kidney disease                                CTGF                                Antagonist        Fully human     NR                          NR                      NR
  Busse et al[@b82-dddt-10-4005]                 2010   MEDI-563                    Immunology (asthma)                                    IL5R-alpha                          Antagonist        Humanized       NR                          NR                      NR
  Riddle et al[@b83-dddt-10-4005]                2011   MDX-1303                    Infection (anthrax)                                    *B. anthracis* protective antigen   Antagonist        Fully human     Model-based                 Non-human primate       53
  Xu et al[@b84-dddt-10-4005]                    2011   CNTO 136 (sirukumab)        Immunology (rheumatoid arthritis)                      IL6                                 Antagonist        Fully human     MED-based                   Non-human primate       53
  Martinsson-Niskanen et al[@b85-dddt-10-4005]   2011   TB-403                      Oncology (solid tumor)                                 PIGF                                Antagonist        Humanized       MABEL-based                 Rodent (mouse)          10
  Paz-Ares et al[@b86-dddt-10-4005]              2011   RG7160 (GA201)              Oncology (solid tumor)                                 EGFR                                Antagonist        Humanized       NOAEL-based                 Non-Rodent              .30
  Padhi et al[@b87-dddt-10-4005]                 2011   AMG 785                     Osteoporosis                                           Sclerostin                          Antagonist        Humanized       NOAEL-based                 Rodent                  NR
  Burmester et al[@b88-dddt-10-4005]             2011   CAM-3001 (mavrilimumab)     Immunology (rheumatoid arthritis)                      GM-CSFR-alpha                       Antagonist        Fully human     NR                          NR                      NR
  Rosen et al[@b89-dddt-10-4005]                 2012   TRC105                      Oncology (angiogenesis)                                CD105                               Agonist           Chimeric        Model-based                 Non-human primate       NR
  Morris et al[@b90-dddt-10-4005]                2012   AGS-PSCA                    Oncology (prostate cancer)                             PSCA                                Antagonist        Fully human     PAD-based                   Rodent                  NR
  Curtin et al[@b91-dddt-10-4005]                2012   GNbAC1                      Immunology (multiple sclerosis)                        MSRV-Env protein                    Antagonist        Humanized       MABEL-based                 In vitro                2.3
  Stein et al[@b92-dddt-10-4005]                 2012   REGN727                     Hypercholesterolemia                                   PCSK9                               Antagonist        Fully human     PAD-based                   Non-rodent              NR
  Zonder et al[@b93-dddt-10-4005]                2012   Anti-CS1 (elotuzumab)       Oncology (multiple myeloma)                            CS1                                 Antagonist        Humanized       PAD-based                   Rodent                  NR
  Abila et al[@b94-dddt-10-4005]                 2013   GSK249320                   Stroke                                                 Myelin-associated glycoprotein      Antagonist        Humanized       NR                          Rodent and non-rodent   NR
  Goldwater et al[@b95-dddt-10-4005]             2013   ASKP1240                    Transplantation                                        CD40                                Antagonist        Fully human     MABEL-based                 In vitro                10
  Hodsman et al[@b96-dddt-10-4005]               2013   GSK679586                   Immunology (asthma)                                    IL13                                Antagonist        Humanized       MABEL-based                 In vitro                NR
  Sandhu et al[@b97-dddt-10-4005]                2013   CNTO888 (carlumab)          Oncology (solid tumor)                                 CCL2                                Antagonist        Fully human     NOAEL-based                 NR                      50
  Infante et al[@b98-dddt-10-4005]               2013   KRN330                      Oncology (advanced colorectal cancer)                  A33                                 Antagonist        Fully human     NOAEL-based                 Non-human primate       300
  Vugmeyster et al[@b99-dddt-10-4005]            2013   TAM-163                     Body weight modulation                                 Tyrosine receptor kinase-B          Agonist           Humanized       MABEL-based                 Non-human primate       400
  Reilly et al[@b100-dddt-10-4005]               2013   OPN-305                     Transplantation                                        TLR2                                Antagonist        Humanized       NOAEL-based                 Rodent and non-rodent   NR
  Zhu et al[@b101-dddt-10-4005]                  2013   GC33                        Oncology (hepatocellular carcinoma)                    Glypican-3                          Antagonist        Humanized       PAD-based                   Rodent                  NR

**Note:**

The safety factor is a number by which the calculated human equivalence dose is divided to increase the assurance that the first dose will not cause toxicity in humans.[@b24-dddt-10-4005]

**Abbreviations:** CCL2, CC-chemokine ligand 2; CMV, cytomegalovirus; CTLA4, cytotoxic T lymphocyte-associated antigen 4; CTGF, connective tissue growth factor; DR4, TRAIL-R1, tumor necrosis factor (TNF)--related apoptosis-inducing ligand receptor-1; EGFR, epidermal growth factor receptor; HER2, human epidermal growth factor receptor 2; HGF/SF, hepatocyte growth factor/scatter factor; IL6, interleukin-6; IGF1R, insulin like growth factor 1 receptor; GM-CSFR, granulocyte-macrophage colony-stimulating factor receptor; IL2R, interleukin 2 receptor; LPS, lipopolysaccharide; MABEL, minimal anticipated biological effect level; MED, minimum effective dose; MRSD, maximum recommended starting dose; NOAEL, no observed adverse effects level; NR, not reported; PAD, pharmacologically active dose; PD, pharmacodynamics; PSCA, prostate stem cell antigen; PCSK9, proprotein convertase subtilisin/kexin 9; PIGF, placental growth factor; RANKL, RANK ligand; Stx2, Shiga toxin type 2; TRAIL-R2, tumor necrosis factor-related apoptosis-inducing ligand receptor-2; TLR2, toll-like receptor 2; VEGF, vascular endothelial growth factor; VEGFR2, vascular endothelial growth factor receptor-2.
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![Overall proportion of the MRSD determination method in the first-in-human studies with monoclonal antibodies.\
**Note:** The model-based methods included PK model-based, PD model-based, and PK--PD model-based approaches.\
**Abbreviations:** MABEL, minimal anticipated biological effect level; MED, minimum effective dose; MRSD, maximum recommended starting dose; NOAEL, no observed adverse effects level; PAD, pharmacologically active dose; PD, pharmacodynamics; PK, pharmacokinetic.](dddt-10-4005Fig2){#f2-dddt-10-4005}

![Yearly trend of the MRSD determination methods in the first-in-human studies with monoclonal antibodies (1990--2013).\
**Note:** The model-based methods included the PK model-based, PD model-based, and PK--PD model-based approaches.\
**Abbreviations:** MABEL, minimal anticipated biological effect level; MED, minimum effective dose; MRSD, maximum recommended starting dose; NOAEL, no observed adverse effects level; PAD, pharmacologically active dose; PD, pharmacodynamics; PK, pharmacokinetic.](dddt-10-4005Fig3){#f3-dddt-10-4005}

![Number of dose escalation steps by the MRSD determination method in the first-in-human studies with monoclonal antibodies.\
**Notes:** The line across each box, the top edge, and the bottom edge represent the median (solid line), the mean (short dash), the first quartile, and the third quartile, respectively (for the MABEL- or MED-, PAD-, and model-based approaches, the median values were the same as the first quartile values). The horizontal lines connected to the whiskers extending from the box denote the minimum and maximum values, respectively. The filled circles (^•^) indicate outliers, which are defined as either values less than the first quartile minus 1.5 times the interquartile range or values greater than the third quartile plus 1.5 times interquartile range. The model-based methods included the PK model-based, PD model-based, and PK--PD model-based approaches.\
**Abbreviations:** MABEL, minimal anticipated biological effect level; MED, minimum effective dose; MRSD, maximum recommended starting dose; NOAEL, no observed adverse effects level; PAD, pharmacologically active dose; PD, pharmacodynamics; PK, pharmacokinetic.](dddt-10-4005Fig4){#f4-dddt-10-4005}

###### 

Publication year, therapeutic area, and antibody type by MRSD determination method

  Factor             NOAEL-based approach   MABEL- or MED-based approach   PAD-based approach   Model-based approach[\*](#tfn2-dddt-10-4005){ref-type="table-fn"}   Not reported   Total        *P*-value[\#](#tfn3-dddt-10-4005){ref-type="table-fn"}
  ------------------ ---------------------- ------------------------------ -------------------- ------------------------------------------------------------------- -------------- ------------ --------------------------------------------------------
  Publication year                                                                                                                                                                              \<0.05
   1990--2007        4 (12.5%)              2 (6.2%)                       7 (21.9%)            3 (9.4%)                                                            16 (50.0%)     32 (40.5%)   
   2008--2010        8 (28.6%)              3 (10.7%)                      2 (7.1%)             3 (10.7%)                                                           12 (42.9%)     28 (35.4%)   
   2011--2013        5 (26.3%)              6 (31.6%)                      4 (21.1%)            2 (10.5%)                                                           2 (10.5%)      19 (24.1%)   
  Therapeutic area                                                                                                                                                                              0.995
   Oncology          9 (21.9%)              4 (9.8%)                       8 (19.5%)            5 (12.2%)                                                           15 (36.6%)     41 (51.9%)   
   Immunology        3 (21.4%)              3 (21.4%)                      1 (7.1%)             1 (7.1%)                                                            6 (43.0%)      14 (17.7%)   
   Infection         2 (20.0%)              1 (10.0%)                      2 (20.0%)            1 (10.0%)                                                           4 (40.0%)      10 (12.7%)   
   Others            3 (21.4%)              3 (21.4%)                      2 (14.3%)            1 (7.1%)                                                            5 (35.8%)      14 (17.7%)   
  Antibody type                                                                                                                                                                                 0.982
   Murine            0 (0.0%)               1 (25.0%)                      1 (25.0%)            1 (25.0%)                                                           1 (25.0%)      4 (5.1%)     
   Chimeric          1 (10.0%)              1 (10.0%)                      2 (20.0%)            1 (10.0%)                                                           5 (50.0%)      10 (12.7%)   
   Humanized         6 (21.4%)              4 (14.3%)                      4 (14.3%)            2 (7.1%)                                                            12 (43.0%)     28 (35.4%)   
   Fully human       9 (25.7%)              5 (14.3%)                      6 (17.2%)            4 (11.4%)                                                           11 (31.4%)     35 (44.3%)   
   Others            1 (50.0%)              0 (0.0%)                       0 (0.0%)             0 (0.0%)                                                            1 (50.0%)      2 (2.5%)     
  Total              17 (21.5%)             11 (13.9%)                     13 (16.5%)           8 (10.1%)                                                           30 (38.0%)     79 (100%)    

**Notes:** The row percent is shown except for the total, in which the column percent is displayed.

The model-based methods included the PK model-based, PD model-based, and PK--PD model-based approaches.

*P*-values from Fisher's exact test.

**Abbreviations:** MABEL, minimal anticipated biological effect level; MED, minimum effective dose; MRSD, maximum recommended starting dose; NOAEL, no observed adverse effects level; PAD, pharmacologically active dose; PD, pharmacodynamic; PK, pharmacokinetic.

###### 

Safety factors by MRSD determination method

  Factor                                                       NOAEL-based approach (n=14)   MABEL- or MED-based approach (n=8)   PAD-based approach (n=3)   Model-based approach (n=3)   *P*-value[\*](#tfn5-dddt-10-4005){ref-type="table-fn"}
  ------------------------------------------------------------ ----------------------------- ------------------------------------ -------------------------- ---------------------------- --------------------------------------------------------
  Safety factor[\#](#tfn6-dddt-10-4005){ref-type="table-fn"}   41.5 (3.2--1,290)             10 (1--400)                          32.2 (2--322)              53 (6.5--300)                0.416

**Notes:**

*P*-value from Kruskal--Wallis test.

The median (range) is presented. The model-based methods included the PK model-based, PD model-based, and PK-PD model-based approaches.

**Abbreviations:** MABEL, minimal anticipated biological effect level; MED, minimum effective dose; MRSD, maximum recommended starting dose; NOAEL, no observed adverse effects level; PAD, pharmacologically active dose; PD, pharmacodynamics; PK, pharmacokinetic.
